Tempus AI, Inc. - Class A (TEM) Covered Calls

Tempus AI, Inc. is a technology leader advancing precision medicine through a multimodal data operating system. The company leverages artificial intelligence to analyze one of the world’s largest libraries of clinical and molecular data, providing physicians with context-aware insights for personalized patient care. Tempus integrates genomic sequencing with real-world clinical records to accelerate drug discovery and optimize treatment across oncology, neuropsychiatry, and cardiology.

You can sell covered calls on Tempus AI, Inc. - Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TEM (prices last updated Fri 1:55 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Tempus AI, Inc. (TEM) operates an "intelligent diagnostics" platform that connects laboratory testing with a massive library of de-identified clinical data. The company’s core business model is a closed-loop system where genomic sequencing (including solid tumor and liquid biopsy) is enhanced by proprietary AI algorithms. Its primary segments include Genomics (diagnostic testing fees), Data & Services (licensing de-identified data to pharmaceutical companies), and AI Applications (clinical decision support tools like Tempus One).

In 2026, Tempus has successfully expanded beyond oncology into neuropsychiatry and cardiology. The company’s "multimodal" approach—combining DNA/RNA sequencing with longitudinal EHR data and pathology imaging—provides a holistic view of patient health. Its latest AI agents, built on healthcare-specific large language models, allow clinicians to query unstructured medical records using natural language, significantly reducing time-to-insight for complex cases.

Competitive Landscape

Tempus operates in a specialized market where it competes with legacy diagnostic labs and genomic sequencing giants. Its primary advantage is the scale and depth of its clinical data library, which includes over 40 million de-identified research records. This data-first strategy makes it an essential partner for life sciences companies seeking to optimize clinical trial enrollment and biomarker discovery.

Key competitors and peers in the genomic and health AI space include:

1. Guardant Health, Inc. (GH): A primary competitor in liquid biopsy and oncology diagnostics.
2. Natera, Inc. (NTRA): A leader in cell-free DNA testing that competes in oncology and prenatal health.
3. Illumina, Inc. (ILMN): The industry standard for the sequencing hardware used across the Tempus platform.
4. Veeva Systems Inc. (VEEV): A major peer in life sciences cloud data, frequently compared for its role in pharmaceutical R&D.

Strategic Outlook and Innovation

For the 2026 fiscal year, Tempus has issued revenue guidance of approximately $1.59 billion, representing 25% annual growth. The company is strategically focused on its "Data-as-a-Service" (DaaS) business and the commercialization of Minimal Residual Disease (MRD) testing. By scaling its AI-enabled care pathways, Tempus aims to transition toward sustained Adjusted EBITDA profitability while deepening its integration with major hospital systems like NYU Langone and Northwestern Medicine.

Innovation at Tempus is currently led by "Agent Builder," a platform that allows researchers to create specialized AI agents for data abstraction and publications analysis. By moving from purely diagnostic tools to predictive algorithms—such as identifying risk factors before clinical symptoms appear—Tempus is positioning itself as the foundational operating system for 21st-century precision medicine. With a market cap nearing $8 billion and a liquid options market, TEM remains a core vehicle for investors tracking the intersection of AI and healthcare.

Want more examples? TELFY Covered Calls | TEN Covered Calls